KRAS and non-small cell lung carcinoma: There were also significant differences in the frequencies of currently targetable genomic alterations related to FDA‐approved targeted therapies in NSCLC that included a slightly higher frequency of KRAS G12C in MTAP‐intact NSCLC (12% vs. 10%, p = 0.003) and slightly higher frequency of EGFR short variant mutations in MTAP‐lost NSCLC (10% vs. 13%, p < 0.001).